173 related articles for article (PubMed ID: 32093632)
1. The impact of 18F-FDOPA-PET/MRI image fusion in detecting liver metastasis in patients with neuroendocrine tumors of the gastrointestinal tract.
Barachini O; Bernt R; Mirzaei S; Pirich C; Hergan K; Zandieh S
BMC Med Imaging; 2020 Feb; 20(1):22. PubMed ID: 32093632
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
[TBL] [Abstract][Full Text] [Related]
3. Whole-body MRI including diffusion-weighted MRI compared with 5-HTP PET/CT in the detection of neuroendocrine tumors.
Carlbom L; Caballero-Corbalán J; Granberg D; Sörensen J; Eriksson B; Ahlström H
Ups J Med Sci; 2017 Mar; 122(1):43-50. PubMed ID: 27894208
[TBL] [Abstract][Full Text] [Related]
4. The Added Diagnostic Value of
Addeo P; Poncet G; Goichot B; Leclerc L; Brigand C; Mutter D; Romain B; Namer IJ; Bachellier P; Imperiale A
J Gastrointest Surg; 2018 Apr; 22(4):722-730. PubMed ID: 29235002
[TBL] [Abstract][Full Text] [Related]
5. The added diagnostic value of complementary gadoxetic acid-enhanced MRI to
Puhr-Westerheide D; Cyran CC; Sargsyan-Bergmann J; Todica A; Gildehaus FJ; Kunz WG; Stahl R; Spitzweg C; Ricke J; Kazmierczak PM
Cancer Imaging; 2019 Nov; 19(1):73. PubMed ID: 31727170
[TBL] [Abstract][Full Text] [Related]
6. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.
Becherer A; Szabó M; Karanikas G; Wunderbaldinger P; Angelberger P; Raderer M; Kurtaran A; Dudczak R; Kletter K
J Nucl Med; 2004 Jul; 45(7):1161-7. PubMed ID: 15235062
[TBL] [Abstract][Full Text] [Related]
7. Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen.
Mayerhoefer ME; Ba-Ssalamah A; Weber M; Mitterhauser M; Eidherr H; Wadsak W; Raderer M; Trattnig S; Herneth A; Karanikas G
Eur Radiol; 2013 Jul; 23(7):1978-85. PubMed ID: 23471430
[TBL] [Abstract][Full Text] [Related]
8. Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours.
Ambrosini V; Tomassetti P; Rubello D; Campana D; Nanni C; Castellucci P; Farsad M; Montini G; Al-Nahhas A; Franchi R; Fanti S
Nucl Med Commun; 2007 Jun; 28(6):473-7. PubMed ID: 17460538
[TBL] [Abstract][Full Text] [Related]
9. Integrated whole-body PET/MRI with 18F-FDG, 18F-FDOPA, and 18F-FDA in paragangliomas in comparison with PET/CT: NIH first clinical experience with a single-injection, dual-modality imaging protocol.
Blanchet EM; Millo C; Martucci V; Maass-Moreno R; Bluemke DA; Pacak K
Clin Nucl Med; 2014 Mar; 39(3):243-50. PubMed ID: 24152658
[TBL] [Abstract][Full Text] [Related]
10. Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with 18F-FDG PET/CT and Gd-EOB-DTPA-enhanced MRI.
Donati OF; Hany TF; Reiner CS; von Schulthess GK; Marincek B; Seifert B; Weishaupt D
J Nucl Med; 2010 May; 51(5):692-9. PubMed ID: 20395324
[TBL] [Abstract][Full Text] [Related]
11. F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients.
Terroir M; Caramella C; Borget I; Bidault S; Dromain C; El Farsaoui K; Deandreis D; Grimaldi S; Lumbroso J; Berdelou A; Hadoux J; Hescot S; Hartl D; Baudin E; Schlumberger M; Leboulleux S
Thyroid; 2019 Oct; 29(10):1457-1464. PubMed ID: 31530235
[No Abstract] [Full Text] [Related]
12. The combination of hepatobiliary phase with Gd-EOB-DTPA and DWI is highly accurate for the detection and characterization of liver metastases from neuroendocrine tumor.
Hayoz R; Vietti-Violi N; Duran R; Knebel JF; Ledoux JB; Dromain C
Eur Radiol; 2020 Dec; 30(12):6593-6602. PubMed ID: 32601948
[TBL] [Abstract][Full Text] [Related]
13. Myocardial metastases on 6-[18F] fluoro-L-DOPA PET/CT: a retrospective analysis of 116 serotonin producing neuroendocrine tumour patients.
Noordzij W; van Beek AP; Tio RA; van der Horst-Schrivers AN; de Vries EG; van Ginkel B; Walenkamp AM; Glaudemans AW; Slart RH; Dierckx RA
PLoS One; 2014; 9(11):e112278. PubMed ID: 25397775
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH
Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDOPA PET/CT-Guided Radiofrequency Ablation of Liver Metastases from Neuroendocrine Tumours: Technical Note on a Preliminary Experience.
Cazzato RL; Garnon J; Ramamurthy N; Tsoumakidou G; Imperiale A; Namer IJ; Bachellier P; Caudrelier J; Rao P; Koch G; Gangi A
Cardiovasc Intervent Radiol; 2016 Sep; 39(9):1315-21. PubMed ID: 27048487
[TBL] [Abstract][Full Text] [Related]
16. 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation.
Imperiale A; Rust E; Gabriel S; Detour J; Goichot B; Duclos B; Kurtz JE; Bachellier P; Namer IJ; Taïeb D
J Nucl Med; 2014 Mar; 55(3):367-72. PubMed ID: 24343986
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the extent of metastases of gastrointestinal carcinoid tumors using whole-body PET, CT, MRI, PET/CT and PET/MRI.
Seemann MD; Meisetschlaeger G; Gaa J; Rummeny EJ
Eur J Med Res; 2006 Feb; 11(2):58-65. PubMed ID: 16504962
[TBL] [Abstract][Full Text] [Related]
18. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients.
Putzer D; Gabriel M; Kendler D; Henninger B; Knoflach M; Kroiss A; Vonguggenberg E; Warwitz B; Virgolini IJ
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):68-75. PubMed ID: 20168288
[TBL] [Abstract][Full Text] [Related]
19. Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT.
Schmidt S; Dunet V; Koehli M; Montemurro M; Meuli R; Prior JO
Acta Radiol; 2013 Oct; 54(8):837-42. PubMed ID: 23761549
[TBL] [Abstract][Full Text] [Related]
20. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors.
Kauhanen S; Seppänen M; Ovaska J; Minn H; Bergman J; Korsoff P; Salmela P; Saltevo J; Sane T; Välimäki M; Nuutila P
Endocr Relat Cancer; 2009 Mar; 16(1):255-65. PubMed ID: 19088184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
